







an Open Access Journal by MDPI

Targeting TGF- β as a Marker and Pharmacological Target against Cancer

Guest Editor:

Dr. Elisabetta Aldieri

Department of Oncology, University of Torino, 10126 Torino, Italy

Deadline for manuscript submissions:

15 March 2025

Message from the Guest Editor

It is known that Transforming Growth Factor- β (TGF- β) plays a crucial role in carcinogenesis, and its alteration has development heen associated to cancer and/or invasiveness, depending on the cancer stage. TGF- β acts as a driver of tumor progression and metastasis, via some alterations in TGF- β signaling pathway and some molecular events associated to malignant progression. epithelial-mesenchymal transition (EMT), angiogenesis, inhibition of the immune response and various aspects concerning the tumor microenvironment (TME). Thus, TGF- β signature may be considered a predictive marker in improving tumor diagnosis/prognosis, and TGF- β inhibition has been demonstrated to reduce tumor growth and prevent cancer metastasis.

Based on these considerations, this Special Issue will focus on identifying TGF- β , and its related targets in the signaling pathway, as significant and crucial for improving the preventive and therapeutic approach to cancer.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us